COVID-19 has been previously described as a high rate infection disease with several systemic complications [2,5,6]. Even though chest X-ray and CT-scans are widely used in the primary instrumental assessment of COVID-19 patients [7,8,9], emerging evidences have explored the role of ultrasound in the diagnosis and treatment [10,11,12]. Frequent abnormal ultrasound imaging findings such as B-lines, consolidation areas or alteration of the pleural line have been recently characterized [12]. On the other hand, ultrasound may produce a real-time and dynamic evaluation, even in cases with critical complications of severe COVID-19 pneumonia, such as pneumothorax.
As described in the present report, COVID-19 infection, displaying its lung tropism, may be associated to multiple and diffuse lesions. Our data are consistent to those recently published by Sun et al [13], who explored the outcome of a patient with mediastinal emphysema and pneumothorax. As detailed by Sun et al, pneumothorax could be produced as a consequence of a sudden increase of the alveolar pressure into the pneumonic consolidations [13]. Lung compliance is high compared with other etiologies of ARDS and the rate of barotrauma appears to be low with only 2% developing pneumothorax compared with 25% of those with SARS severe acute respiratory syndrome [5,6]. Accordingly, the alveolar rupture of the patient here described was localized at the consolidated area, as revealed by the CT-scan. Along this line, lung ultrasonography could be performed at patient’s bedside and it could be considered as primary, handy tool to quickly assess and subsequently treat the condition. The integration of ultrasound images with CT images may be effective in the activation of a comprehensive management plan.
In conclusion, this report reminds us of the importance of consider the possibility of lung complications during COVID-19 infections, such as pneumothorax, even in subjects with no history of previous similar events nor predisposing risk factors. In addition, the appearance of these pathological findings and the severity of interstitial lung involvement are not commonly closely related.
This report also highlights the contribute of lung ultrasound to guarantee the appropriate identification and follow-up. We also speculate, according to the pathogenetic mechanism of viral primum movens and known subsequent excessive immune response, that early introduction of antiviral drugs associated with chloroquine and corticosteroids in patients with symptoms suspicious of COVID-19 disease help not only to treat the infection but also to prevent the complications onset. However, more direct observation is needed to confirm this latter assumption.